10-Q: iSpecimen Inc. Reports Q1 2025 Results: Revenue Declines Amid Cost-Cutting Efforts

iSpecimen Inc.'s Q1 2025 revenue decreased by 54% year-over-year, while the company continued to implement cost-cutting measures and address a material weakness in internal controls.

Summary

• iSpecimen Inc. reported a net loss of $1.66 million for the quarter ended March 31, 2025, compared to a net loss of $2.90 million for the same period in 2024.
• Revenue decreased by 54% to $1.06 million, primarily due to a decrease in specimen count.
• The company continued its cost-cutting efforts, resulting in a 49% decrease in total operating expenses.
• iSpecimen is addressing a material weakness in internal control over financial reporting related to sales tax obligations.
• The company's liquidity remains a concern, with a working capital deficit of $3.39 million and cash and cash equivalents of $783,000 as of March 31, 2025.
• Management is focused on generating additional revenues, deferring projects, and eliminating operating expenses to address going concern uncertainties.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant revenue decline and going concern uncertainty, although cost-cutting efforts and active remediation of internal control weaknesses provide some positive signals.

Positives

• Net loss improved from $2.90 million in Q1 2024 to $1.66 million in Q1 2025.
• Operating expenses decreased by 49% due to cost-cutting efforts.
• The company is actively addressing a material weakness in internal control over financial reporting.
• iSpecimen is implementing a next day quote system, which has increased conversion ratios of quotes to purchase orders by 35%.

Negatives

• Revenue decreased by 54% year-over-year.
• The company has a significant working capital deficit of $3.39 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting exists related to sales tax obligations.

Risks

• The company's financial performance is subject to global economic conditions and their impact on customer spending.
• The company may be unsuccessful in increasing revenues or containing operating expenses.
• iSpecimen may be unable to raise additional capital on commercially favorable terms.
• The company's ability to utilize net operating loss carryforwards may be subject to limitations under Section 382 of the Internal Revenue Code.
• The ongoing litigation with Focus Technologies, Inc. could have an adverse effect on the company's business, financial condition, or results of operations.

Future Outlook

Management plans to mitigate conditions that raise substantial doubt about the company's ability to continue as a going concern by generating additional revenues, deferring certain projects and capital expenditures, and eliminating certain future operating expenses.

Management Comments

• Executive management of the company continues to review the company's structure, processes, and resources to evaluate and identify areas for improvement, and has been focused on creating and ensuring a runway for growth and scale for the business.
• We believe that our business will continue to be resilient through a continued industry-wide economic slowdown in life science research, and that we will continue to work on improving our liquidity to address our financial obligations and alleviate possible adverse effects on our business, financial condition, results of operations or prospects.

Industry Context

The company's financial performance is subject to global economic conditions and their impact on levels of spending by customer research organizations, particularly discretionary spending for procurement of specimens used for research.

Comparison to Industry Standards

• It is difficult to compare iSpecimen's results directly to industry standards due to the company's unique marketplace model.
• Comparable companies in the biospecimen procurement space include biobanks and biorepositories, but their business models and financial reporting may differ significantly.
• iSpecimen's focus on technology and a just-in-time procurement model distinguishes it from traditional inventory-based suppliers.

Management Changes

Corporate Governance

Legal Proceedings

• Focus Technologies, Inc. filed a complaint against the company alleging non-payment under agreements related to information technology services.
• The company is opposing Focus's efforts to enforce a settlement agreement and is intending to assert counterclaims against Focus for consequential damages arising from service disruption and failure to perform under the agreements.
• The Court partially granted Focus's Motion for Pre-Judgment Security, requiring the company to open a dedicated bank account and deposit 15% of revenue up to $420,000.

Stakeholder Impact

• Shareholders: The revenue decline and going concern uncertainty may negatively impact shareholder value.
• Employees: Cost-cutting measures, including workforce reductions, may affect employee morale and job security.
• Customers: The company's ability to provide specimens may be affected by supply chain constraints and the litigation with Focus Technologies, Inc.
• Suppliers: The company's focus on high-value suppliers may impact smaller suppliers.

Next Steps

• The company will continue to implement its remediation plan to improve internal control over financial reporting.
• iSpecimen will focus on generating additional revenues, deferring certain projects and capital expenditures, and eliminating certain future operating expenses.
• The company will continue to seek relief from the pre-judgment security in the litigation with Focus Technologies, Inc.

Key Dates

Keywords

iSpecimen, financial results, Q1 2025, revenue, net loss, operating expenses, cost-cutting, internal control, sales tax, liquidity, going concern, biospecimens, marketplace, research, specimens